Saint-Gobain : Hesitation should subside in favor of volatility
Entry price | Target | Stop-loss | Potential |
---|
€34.98 |
€38.7 |
€33.5 |
+10.65% |
---|
From a horizontal accumulation phase, the timing seems good to buy shares in Saint-Gobain and to get ahead of a break-out on the upside of the congestion area.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● In a short-term perspective, the company has interesting fundamentals.
Strengths● The group usually releases upbeat results with huge surprise rates.
● The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.66 for the 2019 fiscal year.
● The company's attractive earnings multiples are brought to light by a P/E ratio at 11.44 for the current year.
Weaknesses● According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
● The company does not generate enough profits, which is an alarming weak point.
● For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.